Journal article icon

Journal article

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.

Abstract:

BACKGROUND: The vascular disrupting agent combretastatin A4 phosphate (CA4P) causes major regression of animal tumours when given as combination therapy. METHODS: Patients with advanced cancer refractory to standard therapy were treated with CA4P as a 10-min infusion, 20 h before carboplatin, paclitaxel, or paclitaxel, followed by carboplatin. RESULTS: Combretastatin A4 phosphate was escalated from 36 to 54 mg m(-2) with the carboplatin area under the concentration curve (AUC) 4-5, from 27 t...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1038/sj.bjc.6605650

Authors


Journal:
British journal of cancer More from this journal
Volume:
102
Issue:
9
Pages:
1355-1360
Publication date:
2010-04-01
DOI:
EISSN:
1532-1827
ISSN:
0007-0920

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP